News Corporation

▲ Bull Case

• ◆REA Group mark-to-market floor creates structural downside protection — at $26/share, the non-REA portfolio (Dow Jones, Move, HarperCollins, News Media) generating ~$1.1B EBITDA is implied at only ~$4.5B, a fraction of intrinsic value even at deep-discount multiples (10x = $11B, roughly 2x the implied value).
• ◆Dow Jones PIB misclassification — market prices Dow Jones at ~10x EBITDA (newspaper peer group) while correct comps (Thomson Reuters, Verisk) trade at 25–35x. Closing the gap to even 18x on $450–500M EBITDA implies $4–5B of hidden value requiring no operational change, only analyst recognition.
• ◆AI licensing at >95% gross margin ($100M/yr via OpenAI + Meta deals) represents ~$2.0B of incremental value at 20x EBITDA unrecognized by the market, with Google, Apple, and Mistral as logical next signatories; combined with Foxtel simplification signaling management's willingness to unlock conglomerate value.

▼ Bear Case

• ◆Murdoch dual-class governance is permanent — Lachlan Murdoch controls majority voting through LGC Holdco, providing no mechanism for minority holders to force corporate action, asset sales, or discount compression, and NWS (Class B, non-voting) holders have zero protective recourse in any governance event.
• ◆REA Group concentration risk — 69% of market cap in a single foreign-listed AUD-denominated subsidiary creates currency risk, Australian housing market cyclicality exposure, and single-point-of-failure dynamics; a 40% REA share price decline to AUD $90 would eliminate the entire SOTP margin of safety.
• ◆Move.com structural competitive threat — CoStar's Homes.com is deploying ~$1B/yr in marketing spend and has grown to ~8% US real estate search market share, threatening Move.com's #2 position; loss of market share below 10% would collapse the $2.0B SOTP contribution to under $500M.

“The central debate is whether Dow Jones should be valued as a legacy newspaper business (~10x EBITDA, reflecting print-industry peer multiples) or as a professional information/data business analogous to Thomson Reuters or Verisk (~25–35x EBITDA). This single re-rating question accounts for $4–5B of SOTP value. Bears argue the conglomerate discount, Murdoch governance premium, and News Media drag are structural and will never close. Bulls argue Foxtel's divestiture, AI licensing deals, and increasing Dow Jones PIB revenue mix are catalysts for partial re-rating. A secondary debate concerns whether REA Group's ASX multiple (~40x P/E) is sustainable given Australian housing market sensitivity and the India expansion's uncertain profitability timeline.”

• ◆Q4 FY2026 earnings (August 2026): Full-year Dow Jones digital subscriber print confirmation and FCF >$900M validation
• ◆New AI licensing deal announcement (Google, Apple, or Mistral): estimated +$2–4/share impact
• ◆Move.com corporate action or strategic review announcement: estimated +$2–5/share impact
• ◆REA Group FY2026 results (August 2026): Australian housing market outlook and India profitability timeline update
• ◆Dow Jones PIB re-rating by sell-side analysts from newspaper to professional information peer group
• ◆Lachlan Murdoch commentary on further portfolio simplification at November 2026 annual shareholder meeting

• ◆REA Group (ASX: REA) share price sustaining below AUD $90 — eliminates SOTP floor thesis entirely (Kill Switch #1)
• ◆Dow Jones digital subscriber count falling below 5.5M for two consecutive quarters — ~$2B SOTP haircut (Kill Switch #2)
• ◆Move.com monthly unique visitor market share falling below 10% of US real estate search — SOTP contribution collapses from $2B to under $500M (Kill Switch #3)
• ◆Murdoch family governance event: contested succession, legal challenge to Lachlan's control, or ACCC/regulatory intervention (Kill Switch #4)
• ◆REA Group announces acquisition larger than AUD $3B — multiple compression, dilution of capital return, and emerging-market risk introduction (Kill Switch #5)
• ◆Australian dollar depreciation reducing USD value of REA stake
• ◆Persistent conglomerate discount with no near-term catalyst — patient value trap risk